Vidal Amanda Ferreira, Ferraz Rafaella Sousa, El-Husny Antonette, Silva Caio Santos, Vinasco-Sandoval Tatiana, Magalhães Leandro, Raiol-Moraes Milene, Barra Williams Fernandes, Pereira Cynthia Lara Brito Lins, de Assumpção Paulo Pimentel, de Brito Leonardo Miranda, Vialle Ricardo Assunção, Santos Sidney, Ribeiro-Dos-Santos Ândrea, Ribeiro-Dos-Santos André M
Laboratory of Human and Medical Genetics, Graduate Program Genetics and Molecular Biology, Federal University of Pará, Belém, Pará, Brazil.
Bettina Ferro de Souza University Hospital, Federal University of Pará, Belém, Pará, Brazil.
BMC Cancer. 2021 Apr 7;21(1):363. doi: 10.1186/s12885-021-08089-9.
Next generation sequencing (NGS) has been a handy tool in clinical practice, mainly due to its efficiency and cost-effectiveness. It has been widely used in genetic diagnosis of several inherited diseases, and, in clinical oncology, it may enhance the discovery of new susceptibility genes and enable individualized care of cancer patients. In this context, we explored a pan-cancer panel in the investigation of germline variants in Brazilian patients presenting clinical criteria for hereditary cancer syndromes or familial history.
Seventy-one individuals diagnosed or with familial history of hereditary cancer syndromes were submitted to custom pan-cancer panel including 16 high and moderate penetrance genes previously associated with hereditary cancer syndromes (APC, BRCA1, BRCA2, CDH1, CDKN2A, CHEK2, MSH2, MSH6, MUTYH, PTEN, RB1, RET, TP53, VHL, XPA and XPC). All pathogenic variants were validated by Sanger sequencing.
We identified a total of eight pathogenic variants among 12 of 71 individuals (16.9%). Among the mutation-positive subjects, 50% were diagnosed with breast cancer and had mutations in BRCA1, CDH1 and MUTYH. Notably, 33.3% were individuals diagnosed with polyposis or who had family cases and harbored pathogenic mutations in APC and MUTYH. The remaining individuals (16.7%) were gastric cancer patients with pathogenic variants in CDH1 and MSH2. Overall, 54 (76.05%) individuals presented at least one variant uncertain significance (VUS), totalizing 81 VUS. Of these, seven were predicted to have disease-causing potential.
Overall, analysis of all these genes in NGS-panel allowed the identification not only of pathogenic variants related to hereditary cancer syndromes but also of some VUS that need further clinical and molecular investigations. The results obtained in this study had a significant impact on patients and their relatives since it allowed genetic counselling and personalized management decisions.
下一代测序(NGS)已成为临床实践中的便捷工具,主要因其高效性和成本效益。它已广泛应用于多种遗传性疾病的基因诊断,并且在临床肿瘤学中,它可能会促进新的易感基因的发现,并实现癌症患者的个体化治疗。在此背景下,我们探索了一个泛癌基因panel,用于调查具有遗传性癌症综合征临床标准或家族史的巴西患者的种系变异。
71名被诊断患有遗传性癌症综合征或有家族病史的个体接受了定制的泛癌基因panel检测,该panel包括16个先前与遗传性癌症综合征相关的高和中度外显率基因(APC、BRCA1、BRCA2、CDH1、CDKN2A、CHEK2、MSH2、MSH6、MUTYH、PTEN、RB1、RET、TP53、VHL、XPA和XPC)。所有致病性变异均通过桑格测序进行验证。
我们在71名个体中的12名(16.9%)中总共鉴定出8个致病性变异。在突变阳性受试者中,50%被诊断患有乳腺癌,且在BRCA1、CDH1和MUTYH中发生了突变。值得注意的是,33.3%是被诊断患有息肉病或有家族病例且在APC和MUTYH中携带致病性突变的个体。其余个体(16.7%)是在CDH1和MSH2中具有致病性变异的胃癌患者。总体而言,54名(76.05%)个体至少存在一个意义未明的变异(VUS),共有81个VUS。其中,7个被预测具有致病潜力。
总体而言,对NGS-panel中的所有这些基因进行分析不仅可以鉴定与遗传性癌症综合征相关的致病性变异,还可以鉴定一些需要进一步临床和分子研究的VUS。本研究获得的结果对患者及其亲属产生了重大影响,因为它有助于进行遗传咨询和个性化管理决策。